CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.60
-0.05 (-0.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.65
Open8.65
Bid0.00 x 4000
Ask0.00 x 3000
Day's Range8.60 - 8.75
52 Week Range6.75 - 15.95
Volume151,577
Avg. Volume328,801
Market Cap466.099M
Beta1.77
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT

    Q1 2018 Cytokinetics Inc Earnings Call

  • Associated Press26 days ago

    Cytokinetics: 1Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 56 cents per share. The biopharmaceutical company posted revenue of $5.3 million in the period. Cytokinetics shares have declined ...

  • Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?
    Simply Wall St.27 days ago

    Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Cytokinetics Incorporated (NASDAQ:CYTK) as an investment opportunity. Anyone interested inRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT

    Q4 2017 Cytokinetics Inc Earnings Call

  • Associated Press3 months ago

    Cytokinetics reports 4Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 75 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed ...

  • What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors
    Simply Wall St.3 months ago

    What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors

    Today, I will be analyzing Cytokinetics Incorporated’s (NASDAQ:CYTK) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, the impactRead More...

  • Benzinga3 months ago

    Cytokinetics Earnings Outlook

    Cytokinetics (NASDAQ: CYTK ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Sell-side analysts ...

  • Capital Cube6 months ago

    ETFs with exposure to Cytokinetics, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytokinetics, Inc. Here are 5 ETFs with the largest exposure to CYTK-US. Comparing the performance and risk of Cytokinetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
    Zacks6 months ago

    Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

    FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

  • 24/7 Wall St.6 months ago

    Cytokinetics Crumbles on Late-Stage Results

    Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesday’s session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, ...

  • SmarterAnalyst6 months ago

    Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes?

    Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders were met with a rude awakening when the firm's lead ALS asset failed to meet the primary endpoint in its Phase III program, leading to the discontinued development of tirasemtiv. However, Cantor analyst Mara Goldstein has not stepped to the sidelines just yet.

  • Benzinga6 months ago

    Why Is Cytokinetics Plunging Today?

    Cytokinetics, Inc. (NASDAQ: CYTK ) shares are plunging in pre-market trading Tuesday on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv ...

  • SmarterAnalyst6 months ago

    Cytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALS

    Cytokinetics, Inc. (NASDAQ:CYTK) investors hit the panic button following the news that the drug maker is discontinuing development of tirasemtiv for amyotrophic lateral sclerosis (ALS), as the Phase III VITALITY-ALS trial did not meet the primary endpoint of change from baseline in slow vital capacity at 24 weeks following randomization or any of the secondary endpoints, evaluated at 48 weeks. Cytokinetics shares reacted to the news, falling nearly 30% to $7.78 in early trading Tuesday. Cytokinetics CEO Robert I. Blum commented, "While we are deeply disappointed by the results of VITALITY-ALS, we remain committed to people with ALS who are fighting this devastating disease and who need new therapies to slow the decline of respiratory function and muscle strength that are key hallmarks of disease progression [...] We have decided to suspend the development of tirasemtiv.

  • TheStreet.com6 months ago

    Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

    The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.

  • Reuters6 months ago

    Cytokinetics' neuro-degenerative drug fails late-stage trial

    Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial. The drug, tirasemtiv, was not statistically significant in slowing ...

  • Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?
    Zacks6 months ago

    Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?

    Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.

  • Is It Too Late To Buy Cytokinetics Incorporated (CYTK)?
    Simply Wall St.6 months ago

    Is It Too Late To Buy Cytokinetics Incorporated (CYTK)?

    Cytokinetics Incorporated (NASDAQ:CYTK), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS in the over the last few months,Read More...

  • Implied Volatility Surging for Cytokinetics (CYTK) Stock Options
    Zacks7 months ago

    Implied Volatility Surging for Cytokinetics (CYTK) Stock Options

    Cytokinetics (CYTK) needs Investors to pay close attention to the stock based on moves in the options market lately.

  • Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock
    Zacks8 months ago

    Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock

    Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.

  • Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : August 29, 2017
    Capital Cube9 months ago

    Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : August 29, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Cytokinetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Capital Cube9 months ago

    ETFs with exposure to Cytokinetics, Inc. : August 21, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytokinetics, Inc. Here are 5 ETFs with the largest exposure to CYTK-US. Comparing the performance and risk of Cytokinetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Cytokinetics CEO: Optimism still there despite ALS drug s...
    CNBC Videos6 months ago

    Cytokinetics CEO: Optimism still there despite ALS drug s...

    Cytokinetics President and CEO Robert Blum speaks to CNBC's Meg Tirrell about the failure of the company's late-stage ALS drug trial and what he sees in future therapies for the disease.